Humacyte Inc (HUMA) Stock Analysis
Verdict: AVOID
Breakthrough HAV tech faces a critical liquidity gap; the model sees a binary bet where clinical success is overshadowed by dilution risk.
Investment score: 38/100
Analysis as of
Is Humacyte Inc stock worth reviewing? The TradeMates thesis
Humacyte offers high-potential bioengineered tissue technology but suffers from a precarious balance sheet and extreme cash burn. With negative equity and a revenue-to-valuation mismatch, the TradeMates model views the risk of near-term share dilution as the primary obstacle to price appreciation.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Humacyte Inc opportunities and risks
What speaks for HUMA
- Revenue Inflection 2028
What speaks against HUMA
- Critical Cash Runway Shortfall
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HUMA | n/a | 59.8x | n/a | -748.5% | -4840.8% | -84.8% |
| PEPG | n/a | 0.0x | n/a | 0.0% | 0.0% | -35.2% |
| CRBP | n/a | 0.0x | n/a | 0.0% | 0.0% | -59.6% |
| CHRS | n/a | 3.1x | n/a | 63.6% | -257.1% | -156.9% |
| KRRO | n/a | 55.4x | n/a | 56.8% | -4477.1% | -64.0% |
| IMUX | n/a | 0.0x | n/a | 0.0% | 0.0% | -41.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -59.6% |
Frequently asked questions about Humacyte Inc (HUMA)
Is HUMA stock a good investment?
The TradeMates model rates Humacyte Inc as AVOID with an investment score of 38/100. Humacyte offers high-potential bioengineered tissue technology but suffers from a precarious balance sheet and extreme cash burn. With negative equity and a revenue-to-valuation mismatch, the TradeMates model views the risk of near-term share dilution as the primary obstacle to price appreciation. This is algorithmic model output, not personal investment advice.
Is HUMA stock a buy?
The TradeMates model verdict for HUMA is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.